Navigation Links
OncoSec Closes $7.75 Million Public Offering
Date:3/28/2012

her treatment alternatives.  OncoSec's core technology is based upon its proprietary use of an electroporation platform, the OncoSec Medical System (OMS), to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine (OMS ElectroImmunotherapy) or chemotherapeutic agents (OMS ElectroChemotherapy). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at www.oncosec.com. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, without limitation, the satisfaction of the closing conditions and our dependence on the investors' commitments to fulfill their obligations in connection with our private placement financing, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks an
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoSec to Present at 10th Annual BioPartnering North America
2. OncoSec Medical Reports Third Quarter 2011 Financial Results
3. OncoSec Announces Clinical Leadership Appointments
4. OncoSec Announces Leadership Team Appointments
5. OncoSec Medical Featured in Medical Device Daily
6. OncoSec Medical Appoints Punit Dhillon as President and CEO
7. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
8. Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
9. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
10. VisionGate Closes $2 Million Financing and Announces Collaboration to Evaluate Its 3D Cell Imaging Platform for Early Lung Cancer Detection
11. Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Mechanicsburg, PA (PRWEB) May 17, 2013 ... with ramp/soak capabilities. The 5R6-900 temperature controller has many ... can be plugged into the wall as a self-contained ... power supply. This distinctive detail makes the device unique, ... , The controller can also be used universally, which ...
(Date:5/17/2013)... N.C., USA (PRWEB) May 17, 2013 ...     Green Globes Certified for sustainability ,     New facility ... pressures , Syngenta unveiled its ... today at the company’s RTP Innovation Center. The first ... company researchers to simulate any agricultural climate and precisely ...
(Date:5/17/2013)... , May 17, 2013  Insero Health, Inc., ... needs in epilepsy and related neurological disorders, is today ... its lead compound INS001 in patients with drug-resistant epilepsy.  ... and Device Trials (AED) Xll meeting by Dr. ... and Chairman of Insero,s Scientific Advisory Board.  In this ...
(Date:5/17/2013)... IAC Industries wants to share with you the ... to set up and furnish a research lab knowing that ... a year’s time. How does a company make choices in ... What is efficient and cost-effective? , The solution was ... The planners at DisperSol determined that the concept of modular ...
Breaking Biology Technology:New Temperature Control Products Announced by Oven Industries Inc. 2Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
... ALTO, Calif., Sept. 27 CV Therapeutics,Inc. (Nasdaq: ... has submitted a,supplemental new drug application (sNDA) to ... expansion to the approved product labeling,for Ranexa(R) (ranolazine ... new indication for first line treatment,of chronic angina ...
... 27 Cattle producers,soon will find that the latest ... safe are as close at hand as their desktop ... is leading to the creation of,software that will help ... production medicine at K-State,s College of,Veterinary Medicine, is involved ...
... of strategic plan, WATERTOWN, Mass., Sept. 27 ... Boston Biomedical Research Institute, an independent,not-for- profit biomedical ... new scientists, a 23% increase in its scientific ... the fruits of a three-year,strategic planning process designed ...
Cached Biology Technology:CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets) 2K-State Research Leading to Software to Help Nation's Cattle Producers Identify Biosecurity Risks, Evaluate Impact of Cow-Calf Diseases Online 2New Scientists Boost Disease-based Research at Boston Biomedical Research Institute 2New Scientists Boost Disease-based Research at Boston Biomedical Research Institute 3
(Date:5/16/2013)... decades, scientists have used ancient shorelines to predict the stability ... of a high shoreline from three million years ago, for ... were thought to be evidence of a high sea ... assumption has led many scientists to think that if the ... may do just the same in our modern, progressively warming ...
(Date:5/16/2013)... cellular layer lining the body,s blood vessels, is ... in thickness, this super-tenuous structure routinely withstands blood ... create a unique and highly dynamic barrier that ... the body,s circulatory system. , It,s also extremely ... physically breached to enable immune cells to ...
(Date:5/16/2013)... S.C. , May 16, 2013 ... in combination with a custom thin film transistor ... highest forensic quality roll image in the smallest ... today. Sherlock, an Appendix F Mobile ID FAP ... a 95% reduction in size and weight when ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... flu interventions must be imposed quickly, if they are ... journal BMC Public Health have shown that ... within the home should reduce infection, but only if ... maintained for a relatively long period. Professor George ...
... that appears not only to be central to the ... a role in muting the high from methamphetamine and ... known as organic cation transporter 3 or oct3, fills ... damage that causes symptoms like tremor, stiffness, slowness of ...
... -- Arizona State University will be home to a new ... in conjunction with a speech delivered by President Barack Obama. ... will pursue advanced scientific research on solar energy conversion based ... capture sunlight and convert it to useful energy. All 46 ...
Cached Biology News:Social separation stops flu spread, but must be started soon 2Brain protein central to both Parkinson's, drug addiction identified 2Brain protein central to both Parkinson's, drug addiction identified 3Brain protein central to both Parkinson's, drug addiction identified 4DOE funds bio-inspired solar fuel center at Arizona State 2DOE funds bio-inspired solar fuel center at Arizona State 3DOE funds bio-inspired solar fuel center at Arizona State 4
... assay for mitochondrial membrane potential detection ... are detected by carboxyfluorescein (FAM)-labelled fluoromethylketone ... non-cytotoxic and bind covalently to the ... the same time the mitochondrial membrane ...
... cells were cultured in DMEM and harvested at ... to keep the antigens in their native forms, ... are arrayed on a 12-well (5 mm) adhesive ... to enhance cellular attachment and to minimize background ...
... CopyControl™ vector can be induced prior to ... provide the stability of single-copy BACs with ... other cloning vectors. The kits provide the ... insert size screening system) necessary to create ...
Screening assay to detect the Listeria monocytogenes in food samples by,DNA amplification and molecular hybridization on a microtiter plate....
Biology Products: